Zepzelca (lurbinectedin) vs Augtyro (repotrectinib)
Zepzelca (lurbinectedin) vs Augtyro (repotrectinib)
Zepzelca (lurbinectedin) is a chemotherapy drug approved for the treatment of adults with metastatic small cell lung cancer (SCLC) that has progressed after prior platinum-based chemotherapy. It works by binding to DNA and inhibiting the transcription process, which is essential for cancer cell proliferation. In contrast, Augtyro (repotrectinib) is an investigational, next-generation tyrosine kinase inhibitor designed for the treatment of cancers with specific genetic alterations in the NTRK genes, ROS1, or ALK, and is not yet approved for any indication as of the last update. When deciding which medicine is right for an individual, it is crucial to consider the specific type of cancer, its genetic makeup, and the patient's prior treatment history, as these factors determine the appropriateness of either Zepzelca or a drug like Augtyro (repotrectinib).
Difference between Zepzelca and Augtyro
| Metric | Zepzelca (lurbinectedin) | Augtyro (repotrectinib) |
|---|---|---|
| Generic name | Lurbinectedin | Repotrectinib |
| Indications | Metastatic Small Cell Lung Cancer (SCLC) | Advanced solid tumors with specific genetic markers (NTRK, ROS1, or ALK positive) |
| Mechanism of action | Inhibits transcription and induces DNA breaks | Tyrosine kinase inhibitor |
| Brand names | Zepzelca | Augtyro |
| Administrative route | Intravenous | Oral |
| Side effects | Myelosuppression, fatigue, increased liver enzymes, nausea, decreased appetite, musculoskeletal pain, and others | Dizziness, constipation, fatigue, edema, myalgia, cognitive effects, and others |
| Contraindications | Hypersensitivity to lurbinectedin or any component of the formulation | Hypersensitivity to repotrectinib or any component of the formulation |
| Drug class | Alkylating drug | Tyrosine kinase inhibitor |
| Manufacturer | Pharma Mar | Turning Point Therapeutics, Inc. |
Efficacy
Zepzelca (Lurbinectedin) for Small Cell Lung Cancer
Zepzelca (lurbinectedin) is a medication specifically approved for the treatment of adults with metastatic small cell lung cancer (SCLC) that has progressed after platinum-based chemotherapy. The efficacy of Zepzelca in this context was demonstrated in a multi-center, single-arm, open-label clinical study. In this study, a significant percentage of patients with relapsed SCLC responded to the treatment. The response rate, which is the proportion of patients with a significant reduction in tumor size, was a key measure of Zepzelca's efficacy. The duration of response (DOR) was also a critical factor, with some patients experiencing a prolonged response to the therapy.
The study showed that Zepzelca could offer a meaningful clinical benefit in a disease setting with limited treatment options. However, it is important to note that the efficacy can vary among individuals, and not all patients with SCLC will respond to Zepzelca. The safety and efficacy of Zepzelca for other types of lung cancer or other diseases have not been established, and its use is not recommended outside of its approved indication.
Augtyro (Repotrectinib) for Non-Small Cell Lung Cancer
As of the knowledge cutoff date in early 2023, Augtyro (repotrectinib) has been under investigation for the treatment of non-small cell lung cancer (NSCLC) with a specific genetic marker, namely ROS1-positive tumors. Repotrectinib is a tyrosine kinase inhibitor that targets ROS1 and TRK kinases, which are known to drive tumor growth in certain subsets of cancer. Clinical trials have been conducted to assess the efficacy of repotrectinib in patients with ROS1-positive NSCLC, particularly in those who have developed resistance to prior ROS1 inhibitors or who are treatment-naive.
The results from early-phase clinical trials have shown promise, with repotrectinib demonstrating a notable response rate in patients with ROS1-positive NSCLC. The duration of response and progression-free survival (PFS) are important measures that are being evaluated to determine the full clinical benefit of repotrectinib in this patient population. While the data from these trials are encouraging, it is important to recognize that the approval status, indications, and efficacy of repotrectinib for NSCLC or other conditions can only be confirmed upon completion of clinical trials and regulatory review.
Regulatory Agency Approvals
Zepzelca
-
Food and Drug Administration (FDA), USA
Augtyro
-
Food and Drug Administration (FDA), USA
Access Zepzelca or Augtyro today
If Zepzelca or Augtyro are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us